To receive daily emails from Breaking Christian News to your inbox CLICK HERE

"Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today." -Dr. Gerald Weissmann

A new ray of hope has broken through the clouded outcomes associated with Alzheimer's disease. A new research report published in January 2013 print issue of the FASEB Journal (Federation of the American Societies for Experimental Biology) by scientists from the National Institutes of Health shows that when a molecule called TFP5 is injected into mice with disease that is the equivalent of human Alzheimer's, symptoms are reversed and memory is restored—without obvious toxic side effects.

"We hope that clinical trial studies in AD patients should yield an extended and a better quality of life as observed in mice upon TFP5 treatment," said Harish C. Pant, Ph.D., a senior researcher involved in the work from the Laboratory of Neurochemistry at the National Institute of Neurological Disorders at Stroke at the National Institutes of Health in Bethesda, MD. "Therefore, we suggest that TFP5 should be an effective therapeutic compound." (Photo by: Cécile Graat)

To make this discovery, Pant and colleagues used mice with a disease considered the equivalent of Alzheimer's. One set of these mice were injected with the small molecule TFP5, while the other was injected with saline as placebo. The mice, after a series of intraperitoneal injections of TFP5, displayed a substantial reduction in the various disease symptoms along with restoration of memory loss. In addition, the mice receiving TFP5 injections experienced no weight loss, neurological stress (anxiety) or signs of toxicity. The disease in the placebo mice, however, progressed normally as expected. TFP5 was derived from the regulator of a key brain enzyme, called Cdk5. The over activation of Cdk5 is implicated in the formation of plaques and tangles, the major hallmark of Alzheimer's disease.

"The next step is to find out if this molecule can have the same effects in people, and if not, to find out which molecule will," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today."

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Student Revival Movement Alive and Well as Hundreds Accept Christ and Thousands Worship Jesus at NC State: 'All Glory to God'

New York Churches Vandalized With 'Anti-Christian' Graffiti by Suspect Carrying LGBT Flag

Sharon Osbourne Tears Up over Trump's Heartfelt Condolence Call after Ozzy's Death

Tariff Dividend? Trump Wants to Give $2,000 to American Taxpayers

US Mint in Philadelphia Presses the Last-ever Penny after 232 Years

Huge Peer-Reviewed Studies Show COVID Vax Linked to Flu, Kidney Disease

CNN Exposes Democrats for Redacting Epstein Docs to Push Fake Anti-Trump Narrative

'Our Kids Will Be Safer': 150 Illegal Immigrant Sex Offenders Arrested in Florida, Noem Announces

'Thank You, Lord!': Hunter Missing For 20 Days Found Alive as God Intervenes With Stunning Miracle

DOJ Launches Investigation after Antifa Mob Attacks TPUSA Event at UC Berkeley

Trump to Sign Groundbreaking Executive Order Bolstering Foster Care

First Openly 'Transgender' Lawmaker in US History Found Guilty of Child Abuse

Supreme Court to Decide Fate of Transgender Sports Bans

Olympic Committee Ready to Slam the Door on Men in Women's Events

Syria Joins the Global Coalition to Defeat the Islamic State

101 Missing Children in Memphis Rescued by US Marshals

House to Vote on Deal to End Longest Government Shutdown in History

President Trump Signs Funding Bill to End the Government Shutdown

I Nearly Died of Alcoholism; but I Found Purpose in Life Rescuing Street Dogs

Red States Eclipse Blue States in Education as ‘Ideological’ Policies Are Blamed: Report

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor